26th Aug 2021 19:27
Renalytix PLC - Cardiff, Wales-based clinical diagnostics for kidney disease - New results shows KidneyIntelX could save 100,000 patients USD1.1 billion over 5 years.
"Savings were driven by more effective pharmacy management and appropriate specialist referral compared to current standard of care for patients at high risk for disease progression and kidney failure," company says.
Continues: "The detailed clinical and cost analysis concluded that health systems and insurance plans would realize these significant cost savings based on slowed disease progression, delayed, or prevented dialysis and transplants, and reduced dialysis crashes."
Current stock price: 940.00 pence, up 6.8% on Thursday
Year-to-date change: up 93%
By Paul McGowan; [email protected]
Copyright 2021 Alliance News Limited. All Rights Reserved.
Related Shares:
Renalytix Plc